Brief: Resverlogix announces fourth positive recommendation from DSMB
28/06/2017 12:00
June 28 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix announces fourth positive recommendation from
data safety monitoring board for phase 3 study of apabetalone
* Says dsmb reviewed available study data and noted that no
safety or efficacy concerns were identified
* Resverlogix corp - recommendation confirms that
apabetalone continues to be safe and well-tolerated
* Says will conduct additional periodic reviews
* Says resverlogix, clinical steering committee, and all
investigators remain blinded to trial data
* Resverlogix corp - remain on track for full enrollment by
fall of 2017
Source text for Eikon: ID:nCNWnhLRYa
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment